Lynparza For Pancreatic Cancer: ODAC's Narrow Support Leaves US FDA In Quandary
Executive Summary
The Oncologic Drugs Advisory Committee voted 7-5 in favor of AstraZeneca's Lynparza for the treatment of gBRCAm pancreatic cancer, leaving the FDA in a dilemma over how much data to require.
You may also be interested in...
US FDA Approval Of Lynparza For Pancreatic Cancer Opens Door For PFS Endpoint In Disease
AstraZeneca's PARP inhibitor Lynparza becomes first US FDA-approved drug for pancreatic cancer based on progression-free survival endpoint, providing regulatory precedent for other sponsors to use that development approach; all other pancreatic cancer drugs had been approved based on an overall survival benefit.
Keytruda's Proposed Bladder Cancer Indication: Is Delaying Cystectomy Really A Benefit?
Oncologic Drugs Advisory Committee members wondered when Keytruda should be used since cystectomy can be curative and waiting could make the surgery more difficult.
FDA Panel Tentative Yes To AZ’s Lynparza In Pancreatic Cancer
Lynparza doubled PFS in metastatic patients with germline mutations in BRCA but the FDA usually wants to see OS data before approving drugs for pancreatic cancer. Its advisory committee narrowly voted in favor of approval of the PARP inhibitor but will the agency follow suit?